Antibodies directed against the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) receptor or programmed cell death-1 (PD-1) receptor have revolutionized the systemic therapy of advanced melanoma [1]. Here, CTLA4 is linked to melanoma.